 NEW HAVEN, Conn., April 26, 2021 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. BioXcel or the Company Nasdaq: BTAI, a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that data from its two pivotal Phase 3 trials SERENITY I II of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II will be presented at the upcoming American Psychiatric Association APA Annual Meeting. The meeting will be held virtually on May 1-3, 2021. 